Decoy Therapeutics Inc (DCOY)

May 02, 2026

Decoy Therapeutics to implement 1-for-12 reverse stock split - Investing.com

May 02, 2026

Apr 27, 2026

Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston - BioSpace

Apr 27, 2026

Apr 27, 2026

Decoy Therapeutics (DCOY) Proxy Filing Summary - Quartr

Apr 27, 2026

Apr 27, 2026

Decoy Therapeutics Inc (FRA:FP11) Stock PDF (Updated: 2026/04/27) - GuruFocus

Apr 27, 2026

Apr 27, 2026

Decoy Therapeutics Showcases Novel Antiviral Therapies in Boston - Intellectia AI

Apr 27, 2026

Apr 27, 2026

Decoy Therapeutics Inc (FRA:FP11) Stock Earnings Transcripts - GuruFocus

Apr 27, 2026

Apr 26, 2026

Salarius Pharmaceuticals stock tumbles after announcing $7 million discounted public offering - MSN

Apr 26, 2026

Apr 23, 2026

Is Decoy (DCOY) stock gaining market share | Q3 2024: EPS Tops ViewsHot Market Picks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 23, 2026

Apr 10, 2026

DCOY Price Today: Decoy Therapeutics Inc. Stock Price, Quote & Chart - MEXC

Apr 10, 2026

Apr 10, 2026

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline - BioSpace

Apr 10, 2026

Apr 09, 2026

Transcript : Decoy Therapeutics Inc.Special Call - marketscreener.com

Apr 09, 2026

Apr 09, 2026

CEO Rick Pierce to outline Decoy's 2026 outlook in April 9 webcast - Stock Titan

Apr 09, 2026

Apr 09, 2026

Decoy Therapeutics outlines antiviral pipeline milestones By Investing.com - Investing.com South Africa

Apr 09, 2026

Apr 09, 2026

Decoy Therapeutics outlines antiviral pipeline milestones - Investing.com

Apr 09, 2026

Apr 09, 2026

Decoy Therapeutics Launches Multi-Virus Antiviral Platform - Intellectia AI

Apr 09, 2026

Apr 09, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm

Apr 09, 2026

Apr 08, 2026

What is the volatility of Decoy (DCOY) Stock | Price at $5.84, Down 0.76%Index Investing - Newser

Apr 08, 2026

Apr 07, 2026

DCOY Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 07, 2026

Apr 06, 2026

Decoy Therapeutics to Participate in Virtual Investor Closing Be - GuruFocus

Apr 06, 2026

Apr 06, 2026

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 - Finviz

Apr 06, 2026

Apr 06, 2026

Is Decoy (DCOY) Stock a Buy Now | DCOY Q4 Earnings: Beats Estimates by $25.32Recovery Stocks - Newser

Apr 06, 2026

Apr 03, 2026

Decoy Therapeutics Inc (STU:FP11) Stock Earnings Transcripts - GuruFocus

Apr 03, 2026

Apr 03, 2026

Decoy Therapeutics Inc (STU:FP11) Stock Price & 30 Year Financial Data - GuruFocus

Apr 03, 2026

Apr 03, 2026

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Bitget

Apr 03, 2026

Apr 03, 2026

DCOY Stock Analysis: Decoy Therapeutics Inc. Slides 7.5% to $5.8 Key Biotech Trends - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 03, 2026

Apr 02, 2026

Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Apr 02, 2026

Apr 02, 2026

Decoy Therapeutics regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Australia

Apr 02, 2026

Apr 02, 2026

Decoy Therapeutics regains Nasdaq minimum bid price compliance - Investing.com

Apr 02, 2026

Apr 02, 2026

Decoy Therapeutics Regains Nasdaq Compliance After Reverse Split - TipRanks

Apr 02, 2026

Apr 02, 2026

Decoy Therapeutics regains compliance with Nasdaq minimum bid price requirement - marketscreener.com

Apr 02, 2026

Apr 02, 2026

Decoy Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement - TradingView

Apr 02, 2026

Apr 02, 2026

Decoy Therapeutics regains Nasdaq minimum bid compliance after reverse split - TradingView

Apr 02, 2026

Apr 02, 2026

Decoy Therapeutics (DCOY) restores Nasdaq bid-price compliance after reverse split - Stock Titan

Apr 02, 2026

Apr 01, 2026

DCOY Stock Analysis: Biotech Decoy Therapeutics Inc. Rises 1.43 Percent to 6.62 Dollars - Cổng thông tin điện tử Tỉnh Sơn La

Apr 01, 2026

Mar 31, 2026

DCOY: 2025 net loss rose to $12.5M, with cash runway into late 2026 but going concern risk persists - TradingView

Mar 31, 2026

Mar 31, 2026

Decoy Therapeutics 10-K: Net loss $12.52M, EPS $(129.10) - TradingView — Track All Markets

Mar 31, 2026

Mar 31, 2026

Decoy Therapeutics (NASDAQ: DCOY) details AI antiviral platform, merger and reverse stock splits - Stock Titan

Mar 31, 2026

Mar 31, 2026

Decoy Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 31, 2026

Mar 30, 2026

Decoy Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 30, 2026

Mar 26, 2026

Total liabilities & shareholders' equities of Decoy Therapeutics Inc. – FWB:FP11 - TradingView

Mar 26, 2026

Mar 23, 2026

Nabriva Therapeutics (NASDAQ:NBRV) and Decoy Therapeutics (NASDAQ:DCOY) Head to Head Survey - Defense World

Mar 23, 2026

Mar 23, 2026

If You Invested $1,000 in Salarius Pharmaceuticals Inc (SLRX) - Stock Titan

Mar 23, 2026

Mar 20, 2026

Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | | US79400X6022 - marketscreener.com

Mar 20, 2026

Mar 20, 2026

Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | FP11 | US79400X6022 - marketscreener.com

Mar 20, 2026

Mar 19, 2026

Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | DCOY | US79400X6022 - marketscreener.com

Mar 19, 2026

Mar 15, 2026

Decoy Therapeutics partners with Quantori on AI peptide platform By Investing.com - Investing.com Nigeria

Mar 15, 2026

Mar 12, 2026

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform - Lelezard

Mar 12, 2026